Analyst Adjusts Price Target for uniQure (NASDAQ:QURE) Amid Mixed Financials and Clinical Progress

Font: Financial Modeling Prep  • May 06, 2026

• Analyst H.C. Wainwright lowered the price target for uniQure to $50.00, indicating a potential upside of 68.95% from its trading price at the time of the rating.
• uniQure reported mixed Q1 financial results, with a wider loss of $0.85 per share but increased revenue of $3.56 million that still missed analyst estimates by nearly 49%.
• Despite revenue challenges, the gene therapy company is making significant progress in its clinical programs, including an upcoming FDA meeting for its Huntington's disease treatment, supported by a strong cash position of $586.60 million.

uniQure (NASDAQ:QURE) is a gene therapy company that focuses on developing treatments for patients with severe genetic diseases. The company's main work involves creating one-time administered therapies that aim to provide long-lasting benefits. Its pipeline includes potential treatments for conditions like Huntington's disease, Fabry disease, and temporal lobe epilepsy.

Patrick Trucchio, an analyst at H.C. Wainwright, has adjusted the price target for uniQure, lowering it to $50.00 from a previous $70.00. When this rating was published, the stock was trading at $21.64 per share. The new target suggests a potential upside of approximately 68.95% from that price.

This adjustment comes as the company reports mixed financial results. In its first quarter, uniQure announced a loss of $0.85 per share. This was a wider loss compared to the $0.82 per share loss from the same period a year ago, though it was slightly better than what analysts had estimated.

On the revenue side, the company posted $3.56 million for the quarter, a notable increase from $1.57 million in the prior-year quarter. However, as highlighted by Zacks, this figure missed revenue estimates by nearly 49%. This marks the fourth consecutive quarter that the company has not met revenue expectations.

Despite the revenue miss, uniQure is making progress with its key drug candidates. As reported by GlobeNewswire, the company has a meeting scheduled with the U.S. FDA for its Huntington's disease treatment, AMT-130. It also plans to submit a Marketing Authorisation Application in the United Kingdom in the third quarter of 2026.

The company maintains a strong financial position to support these efforts. It holds $586.60 million in cash and investments, which provides a financial runway into the second half of 2029. This stability is crucial as it advances its clinical programs, including those for epilepsy and Fabry disease.